<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01923259</url>
  </required_header>
  <id_info>
    <org_study_id>DNI-P0-653</org_study_id>
    <nct_id>NCT01923259</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of Donepezil Hydrochloride Tablets 23 mg Under Fed Condition</brief_title>
  <official_title>Single Dose Crossover Comparative Bioavailability Study of Donepezil 23 mg Tablets in Healthy Male and Female Volunteers / Fed State</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate and compare the relative bioavailability and therefore the bioequivalence of two
      different formulations of donepezil after a single oral dose administration under fed
      conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single center, randomized, single dose, laboratory-blinded, 2-period, 2-sequence, crossover
      study under fed conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve (AUC)</measure>
    <time_frame>1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 18, 24, 48 and 72 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">94</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Donepezil Hydrochloride Tablets, 23 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Donepezil Hydrochloride Tablets, 23 mg of Dr.Reddy's Laboratories Ltd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aricept</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AriceptÂ® 23 mg tablet of Eisai Inc</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil</intervention_name>
    <description>Donepezil Hydrochloride tablets,23 mg</description>
    <arm_group_label>Donepezil Hydrochloride Tablets, 23 mg</arm_group_label>
    <arm_group_label>Aricept</arm_group_label>
    <other_name>Aricept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female volunteer

          2. Volunteer aged of at least 18 years but not older than 45 years

          3. Volunteer with a body mass index (BMI) greater than or equal to 21 and below 30 kg/m2

          4. Volunteer with a body weight greater than or equal to 60 kg.

          5. Light-, non- or ex-smokers. A light smoker is defined as someone smoking 10 cigarettes
             or less per day for at least 3 months before day 1 of this study. An ex-smoker is
             defined as someone who completely stopped smoking for at least 12 months before day 1
             of this study.

          6. Availability for the entire study period

          7. Motivated volunteer and absence of intellectual problems likely to limit the validity
             of consent to participate in the study or the compliance with protocol requirements;
             ability to cooperate adequately; ability to understand and observe the instructions of
             the physician or designee.

          8. Clinical laboratory values within the laboratory's stated normal range; if not within
             this range, they must be without any clinical significance

          9. Have no clinically significant diseases captured in the medical history or evidence of
             clinically significant findings on physical examination and/or clinical laboratory
             evaluations (hematology, biochemistry, ECG and urinalysis)

         10. Willingness to adhere to the protocol requirements as evidenced by the informed
             consent form (ICF) duly read, signed and dated by the volunteer

        Exclusion Criteria

          1. Seated pulse rate less than 50 bpm at screening

          2. Seated blood pressure below 105/60 mmHg at screening

          3. Seated blood pressure below 105/60 mmHg before drug administration

          4. Females who are pregnant or are lactating

          5. Females of childbearing potential who refuse to use an acceptable contraceptive
             regimen throughout the entire duration of the study

          6. History of significant hypersensitivity to donepezil, piperidine derivatives,
             scopolamine, or any related products (including excipients of the formulations) as
             well as severe hypersensitivity reactions (like angioedema) to any drugs

          7. Presence of significant gastrointestinal, liver or kidney disease, or any other
             conditions known to interfere with the absorption, distribution, metabolism or
             excretion of drugs or known to potentiate or predispose to undesired effects

          8. History of significant gastrointestinal, liver or kidney disease that may affect drug
             bioavailability

          9. Presence of significant cardiovascular, pulmonary, hematologic, neurological,
             psychiatric, endocrine, immunologic or dermatologic disease

         10. Suicidal tendency, history of or disposition to seizures, state of
             confusion,clinically relevant psychiatric diseases

         11. Presence of out-of-range cardiac interval (PR &lt; 110 msec, PR &gt; 200 msec, QRS &gt;110 msec
             and QTc &gt; 440 msec) on the screening ECG or other clinically significant ECG
             abnormalities.

         12. Use of ASA or NSAIDs (or any product containing ASA or NSAIDs) in the previous 7 days
             before day 1 of this study

         13. Use of diphenhydramine in the previous 10 hours before day 1 of this study

         14. Known presence of rare hereditary problems of galactose and /or lactose intolerance

         15. Known presence of glaucoma or a predisposition to angle-closure glaucoma

         16. Maintenance therapy with any drug, or significant history of drug dependency or
             alcohol abuse (&gt; 3 units of alcohol per day, intake of excessive alcohol, acute or
             chronic)

         17. Any clinically significant illness in the previous 28 days before day 1 of this study

         18. Use of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450
             (CYP) enzymes (such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin,
             fluconazole, ketoconazole, diltiazem and HIV antivirals) and strong inducers of CYP
             enzymes (such as barbiturates, carbamazepine, glucocorticoids, phenytoin, rifampin and
             St John's Wort), in the previous 28 days before day 1 of this study

         19. Any history of tuberculosis and/or prophylaxis for tuberculosis

         20. Positive urine screening of alcohol and/or drugs of abuse

         21. Positive results to HIV, HBsAg or anti-HCV tests

         22. Females who are pregnant according to a positive serum pregnancy test

         23. Volunteers who took an Investigational Product (in another clinical trial) or donated
             50 mL or more of blood in the previous 28 days before day 1 of this study.

         24. Donation of 500 mL or more of blood (Canadian Blood Services, Hema-Quebec, clinical
             studies, etc.) in the previous 56 days before day 1 of this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Sicard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Algorithme Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Algorithme Pharma Inc.</name>
      <address>
        <city>Mount Royal</city>
        <state>Quebec</state>
        <zip>H3P 3P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2013</study_first_submitted>
  <study_first_submitted_qc>August 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2013</study_first_posted>
  <last_update_submitted>August 13, 2013</last_update_submitted>
  <last_update_submitted_qc>August 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

